ClinicalTrials.gg
CompletedNCT02469246Updated Oct 25, 2019Results posted

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

A Phase 3 interventional study of F/TAF and ABC/3TC in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 80 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-25.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
567
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching abacavir/lamivudine (ABC/3TC) fixed-dose combination (FDC) tablets to emtricitabine/tenofovir alafenamide (F/TAF) FDC tablets versus maintaining ABC/3TC in human immunodeficiency virus type 1 (HIV-1) infected adults who are virologically suppressed on regimens containing ABC/3TC.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • HIV
  • HIV-1 Positive
  • Virologically-Suppressed
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The ability to understand and sign a written form
  • On antiretroviral regimen containing ABC/3TC FDC in combination with one 3rd agent for ≥ 6 consecutive months prior to screening
  • Plasma -1 RNA levels \< 50 copies/mL for ≥ 6 months preceding the screening visit (measured at least twice using the same assay) and without experiencing two consecutive HIV-1 RNA above detectable levels after achieving a confirmed (two consecutive) HIV-1 RNA below detectable levels on the current regimen in the past year
  • Plasma HIV-1 RNA should be \< 50 copies/mL at the screening visit
  • Normal
  • Estimated (GFR) ≥ 50 mL/min according to the formula for creatinine clearance
  • Hepatic transaminases ( and ALT) ≤ 5 × (ULN)
  • Total ≤ 1.5 mg/dL, or normal direct bilirubin
  • Adequate hematologic function
  • Serum amylase ≤ 5 × ULN
  • Females of and males must agree to utilize highly effective methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following the last dose of study drug

Key Exclusion Criteria:

  • A new AIDS-defining condition diagnosed within the 30 days prior to screening
  • surface antigen (HBsAg) positive
  • Individuals experiencing decompensated cirrhosis
  • Individuals receiving ongoing treatment with bisphosphonate to treat bone disease (eg, osteoporosis)
  • Pregnant or lactating females
  • Have an implanted defibrillator or pacemaker
  • Current alcohol or substance use judged by the investigator to potentially interfere with study compliance
  • A history of within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma.
  • Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1 Visit
  • Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements
  • Participation in any other clinical trial (including observational trials) without prior approval
  • Medications excluded due to the potential for interaction with emtricitabine (FTC), TAF, ABC or 3TC

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
567 participants (actual)

Study arms

  • Experimental
    F/TAF (Double-Blind)

    F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded.

    Drug: F/TAF · Drug: ABC/3TC Placebo · Drug: 3rd ARV agent

  • Active comparator
    ABC/3TC (Double-Blind)

    ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded.

    Drug: ABC/3TC · Drug: F/TAF Placebo · Drug: 3rd ARV agent

  • Experimental
    Open-Label F/TAF

    After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.

    Drug: F/TAF

Interventions

  • DrugF/TAF

    Drug pages: Emtricitabine · Tenofovir alafenamide

    200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily

    Also known as: Descovy®

  • DrugABC/3TC

    600/300 mg FDC tablets administered orally once daily

  • DrugABC/3TC Placebo

    Tablets administered orally once daily

  • DrugF/TAF Placebo

    Tablets administered orally once daily

  • Drug3rd ARV agent

    An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  2. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  3. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  4. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  5. Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  6. Change From Baseline in CD4 Cell Count at Week 48

    Time frame: Baseline; Week 48

  7. Change From Baseline in CD4 Cell Count at Week 96

    Time frame: Baseline; Week 96

  8. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

    Time frame: Baseline; Week 48

  9. Percent Change From Baseline in Hip BMD at Week 96

    Time frame: Baseline; Week 96

  10. Percent Change From Baseline in Spine BMD at Week 48

    Time frame: Baseline; Week 48

  11. Percent Change From Baseline in Spine BMD at Week 96

    Time frame: Baseline; Week 96

07

Results

Posted Jun 11, 2018

Participant flow

Participants were enrolled at study sites in North America and Europe. The first participant was screened on 29 June 2015. The last study visit occurred on 13 March 2019.

Double-Blind Phase
Participant flow — Double-Blind Phase
MilestoneF/TAFABC/3TC
Started285282
Completed218226
Not completed6756
Withdrew: Randomized and never treated56
Withdrew: Adverse event129
Withdrew: Death20
Withdrew: Lack of efficacy21
Withdrew: Investigator's discretion88
Withdrew: Non-compliance with study drug31
Withdrew: Protocol violation11
Withdrew: Withdrew consent2525
Withdrew: Lost to follow-up95
Open-Label Extension (OLE)
Participant flow — Open-Label Extension (OLE)
MilestoneF/TAFABC/3TC
Started65
Completed65
Not completed00

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm
percentage of participantsF/TAFABC/3TC
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm88.692.4
Statistical analysis
  • F/TAF vs ABC/3TC · Fisher Exact · p = 0.15 · Difference in percentages: -3.8 · 95.002% CI -8.9 to 1.1The difference in percentages and its 95.002% CI were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm
percentage of participantsF/TAFABC/3TC
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm82.188.4
Statistical analysis
  • F/TAF vs ABC/3TC · Fisher Exact · p = 0.042 · Difference in percentages: -6.3 · 95% CI -12.3 to -0.3The difference in percentages and its 95% CI were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm
percentage of participantsF/TAFABC/3TC
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm1.80.7
Statistical analysis
  • F/TAF vs ABC/3TC · Fisher Exact · p = 0.45 · Difference in percentages: 1.1 · 95.002% CI -1.0 to 3.5The difference in percentages and its 95.002% CI were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm
percentage of participantsF/TAFABC/3TC
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm2.51.1
Statistical analysis
  • F/TAF vs ABC/3TC · Fisher Exact · p = 0.34 · Difference in percentages: 1.4 · 95% CI -1.0 to 4.2The difference in percentages and its 95% CI were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm
percentage of participantsF/TAFABC/3TC
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 as Determined by the FDA-Defined Snapshot Algorithm85.787.3
Statistical analysis
  • F/TAF vs ABC/3TC · Fisher Exact · p = 0.62 · Difference in percentages: -1.6 · 95% CI -7.4 to 4.2The difference in percentages and its 95% CI were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm
percentage of participantsF/TAFABC/3TC
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96 as Determined by the FDA-Defined Snapshot Algorithm80.486.2
Statistical analysis
  • F/TAF vs ABC/3TC · Fisher Exact · p = 0.069 · Difference in percentages: -5.9 · 95% CI -12.2 to 0.4The difference in percentages and its 95% CI were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryChange From Baseline in CD4 Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4 Cell Count at Week 48
cells/µLF/TAFABC/3TC
Change From Baseline in CD4 Cell Count at Week 48-30 ± 152.32 ± 171.2
Statistical analysis
  • F/TAF vs ABC/3TC · ANOVA · p = 0.026 (P-value was adjusted by the third agent stratum (boosted protease inhibitors vs. others).) · Difference in lsm: -32 · 95% CI -61 to -4Difference in LSM and its 95% CI were adjusted by the third agent stratum (boosted protease inhibitors vs. others).
SecondaryChange From Baseline in CD4 Cell Count at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · cells/μL
Change From Baseline in CD4 Cell Count at Week 96
cells/μLF/TAFABC/3TC
Change From Baseline in CD4 Cell Count at Week 96-29 ± 160.710 ± 178.2
Statistical analysis
  • F/TAF vs ABC/3TC · ANOVA · p = 0.013 (P-value was adjusted by the third agent stratum (boosted protease inhibitors vs. others).) · Difference in lsm: -39 · 95% CI -70 to -8Difference in LSM and its 95% CI were adjusted by the third agent stratum (boosted protease inhibitors vs. others).
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
percent changeF/TAFABC/3TC
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 480.246 ± 2.29140.086 ± 2.3315
Statistical analysis
  • F/TAF vs ABC/3TC · ANOVA · p = 0.40 (P-value was adjusted by the third agent stratum (boosted protease inhibitors vs. others).) · Difference in lsm: 0.179 · 95% CI -0.240 to 0.598Difference in LSM and its 95% CI were adjusted by the third agent stratum (boosted protease inhibitors vs. others).
SecondaryPercent Change From Baseline in Hip BMD at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Hip BMD at Week 96
percent changeF/TAFABC/3TC
Percent Change From Baseline in Hip BMD at Week 960.169 ± 2.72770.021 ± 2.7212
Statistical analysis
  • F/TAF vs ABC/3TC · ANOVA · p = 0.53 (P-value was adjusted by the third agent stratum (boosted protease inhibitors vs. others).) · Difference in lsm: 0.165 · 95% CI -0.348 to 0.678Difference in LSM and its 95% CI were adjusted by the third agent stratum (boosted protease inhibitors vs. others).
SecondaryPercent Change From Baseline in Spine BMD at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 48
percent changeF/TAFABC/3TC
Percent Change From Baseline in Spine BMD at Week 480.081 ± 3.0051-0.052 ± 3.7550
Statistical analysis
  • F/TAF vs ABC/3TC · ANOVA · p = 0.63 (P-value was adjusted by the third agent stratum (boosted protease inhibitors vs. others).) · Difference in lsm: 0.151 · 95% CI -0.465 to 0.767Difference in LSM and its 95% CI were adjusted by the third agent stratum (boosted protease inhibitors vs. others).
SecondaryPercent Change From Baseline in Spine BMD at Week 96
Time frame:
Baseline; Week 96
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 96
percent changeF/TAFABC/3TC
Percent Change From Baseline in Spine BMD at Week 960.178 ± 3.88810.235 ± 4.3066
Statistical analysis
  • F/TAF vs ABC/3TC · ANOVA · p = 0.89 (P-value was adjusted by the third agent stratum (boosted protease inhibitors vs. others).) · Difference in lsm: -0.056 · 95% CI -0.825 to 0.713Difference in LSM and its 95% CI were adjusted by the third agent stratum (boosted protease inhibitors vs. others).

Adverse events

Collected over First dose date to last dose date (maximum duration: 168 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
F/TAF (Double-Blind Phase)5/280 (1.8%)55/280 (19.6%)190/280 (67.9%)
ABC/3TC (Double-Blind Phase)0/276 (0%)32/276 (11.6%)199/276 (72.1%)
Open-Label F/TAF From F/TAF0/6 (0%)0/6 (0%)1/6 (16.7%)
Open-Label F/TAF From ABC/3TC0/5 (0%)0/5 (0%)2/5 (40%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventF/TAF (Double-Blind Phase)ABC/3TC (Double-Blind Phase)Open-Label F/TAF From F/TAFOpen-Label F/TAF From ABC/3TC
PneumoniaInfections and infestations5/2802/2760/60/5
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2803/2760/60/5
Deep vein thrombosisVascular disorders2/2803/2760/60/5
Acute kidney injuryRenal and urinary disorders3/2800/2760/60/5
GastroenteritisInfections and infestations0/2802/2760/60/5
UrosepsisInfections and infestations1/2802/2760/60/5
Chest painGeneral disorders2/2800/2760/60/5
Type 2 diabetes mellitusMetabolism and nutrition disorders2/2800/2760/60/5
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2800/2760/60/5
Suicide attemptPsychiatric disorders2/2801/2760/60/5
Most frequent other events
Showing 10 of 22
Most frequent other events
EventF/TAF (Double-Blind Phase)ABC/3TC (Double-Blind Phase)Open-Label F/TAF From F/TAFOpen-Label F/TAF From ABC/3TC
NasopharyngitisInfections and infestations57/28049/2760/61/5
RhinitisInfections and infestations7/2806/2760/61/5
Renal colicRenal and urinary disorders1/2800/2760/61/5
Upper respiratory tract infectionInfections and infestations36/28046/2760/60/5
Spinal painMusculoskeletal and connective tissue disorders0/2801/2761/60/5
DiarrhoeaGastrointestinal disorders30/28037/2760/60/5
CoughRespiratory, thoracic and mediastinal disorders34/28030/2760/60/5
Back painMusculoskeletal and connective tissue disorders24/28031/2760/60/5
HeadacheNervous system disorders31/28025/2760/60/5
ArthralgiaMusculoskeletal and connective tissue disorders28/28029/2760/60/5

Baseline characteristics

The Safety Analysis Set included all randomized participants who received at least one dose of study drug. Participants were grouped according to the treatment they actually received.

Age, Continuous
Age, Continuous(years)F/TAFABC/3TCTotal
Mean51 ± 9.451 ± 9.351 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)F/TAFABC/3TCTotal
Female4061101
Male240215455
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)F/TAFABC/3TCTotal
Hispanic or Latino161935
Not Hispanic or Latino264257521
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)F/TAFABC/3TCTotal
American Indian or Alaska Native101
Asian5510
Black6466130
White205199404
Other5611
Region of Enrollment
Region of Enrollment(Participants)F/TAFABC/3TCTotal
Belgium4610
Canada9817
Denmark437
France181735
Germany201939
Ireland9817
Italy261743
Spain323466
Sweden347
United Kingdom5059109
United States105101206
HIV-1 RNA Category
HIV-1 RNA Category(Participants)F/TAFABC/3TCTotal
< 50 copies/mL278273551
≥ 50 copies/mL235
CD4 Cell Count
CD4 Cell Count(cells/µL)F/TAFABC/3TCTotal
Mean703 ± 298.7727 ± 275.2715 ± 287.3
CD4 Cell Count Category
CD4 Cell Count Category(Participants)F/TAFABC/3TCTotal
< 50 cells/µL011
≥ 50 to < 200 cells/µL000
≥ 200 to < 350 cells/µL201636
≥ 350 to < 500 cells/µL563894
≥ 500 cells/µL204221425

1 further baseline measures are reported on the registry.

08

Study locations

80 sites
  • Spectrum Medical Group
    Phoenix, Arizona, United States
  • Pacific Oaks Medical Group
    Beverly Hills, California, United States
  • University of California San Diego (UCSD)
    La Jolla, California, United States
  • Anthony Mills, MD, Inc.
    Los Angeles, California, United States
  • Peter J. Ruane, MD, Inc.
    Los Angeles, California, United States
  • Highland Hospital - Alameda Health System
    Oakland, California, United States
  • La Playa Medical Group and Clinical Research
    San Diego, California, United States
  • Capial Medical Associates
    Washington, District of Columbia, United States
  • Dupont Circle Physician's Group
    Washington, District of Columbia, United States
  • Whitman-Walker Health
    Washington, District of Columbia, United States
  • Gary J. Richmond,M.D.,P.A.
    Fort Lauderdale, Florida, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida, United States
  • Orlando Immunology Center
    Orlando, Florida, United States
  • Triple O Research Institute PA
    West Palm Beach, Florida, United States
  • Atlanta ID Group
    Atlanta, Georgia, United States
  • Howard Brown Health Center
    Chicago, Illinois, United States
  • University of Louisville
    Louisville, Kentucky, United States
  • LSU Health Sciences Center
    New Orleans, Louisiana, United States
  • Be Well Medical Center
    Berkley, Michigan, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota, United States
  • The KC CARE Clinic
    Kansas City, Missouri, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri, United States
  • Saint Michael's Medical Center
    Newark, New Jersey, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey, United States
  • Southwest CARE Center
    Santa Fe, New Mexico, United States
  • Montefiore Medical Center
    Bronx, New York, United States
  • Philadelphia FIGHT
    Philadelphia, Pennsylvania, United States
  • Central Texas Clinical Research
    Austin, Texas, United States
  • AIDS Arms, Inc
    Dallas, Texas, United States
  • Tarrant County Infectious Disease Associates
    Fort Worth, Texas, United States
  • Gordon E. Crofoot MD PA
    Houston, Texas, United States
  • Therapeutic Concepts, PA
    Houston, Texas, United States
  • Peter Shalit, MD
    Seattle, Washington, United States
  • UZ Gent
    Ghent, Belgium
  • Centre Hospitalier Universitaire CHU Sart Tilman Liege
    Liege, Belgium
  • Clinique medicale l'Actuel
    Montreal, Canada
  • Maple Leaf Research
    Toronto, Canada
  • Spectrum Health
    Vancouver, Canada
  • Vancouver ID Research and Care Centre Society
    Vancouver, Canada
  • Hvidovre Hospital
    Copenhagen, Denmark
  • CHU - Groupe Saint-Andre
    Bordeaux, France
  • CHU de Bordeaux
    Bordeaux, France
  • C.H.U. de Nantes
    Nantes, France
  • CHR Orleans la Source
    Orleans, France
  • Chu Tours
    Tours, France
  • ICH Study Center Hamburg
    Bielefeld, Germany
  • Medizinische Universitatsklinik
    Bonn, Germany
  • Universitatsklinikum Essen
    Essen, Germany
  • Johann Wolfgang Goethe-University Hospital
    Frankfurt, Germany
  • ifi-Studien und Projekte GmbH an der Asklepiosklinik St. Georg
    Hamburg, Germany
  • Universitatsklinikum Hamburg-Eppendorf
    Hamburg, Germany
  • Klinikum der Universitaet Koln
    Koln, Germany
  • Universitätsklinikum München
    Munich, Germany
  • Mater Misericordiae University Hospital
    Dublin 7, Ireland
  • Saint James's Hospital
    Dublin, Ireland
  • University of Brescia
    Brescia, Italy
  • Azienda Ospedaliera Luigi Sacco
    Milano, Italy
  • Fondazione IRCCS San Raffaele del Monte Tabor
    Milano, Italy
  • Azienda Ospedaliero Universitaria Policlinico di Modena
    Modena, Italy
  • Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.
    Roma, Italy
  • Ospedale Amedeo di Savoia - Specializzato Malattie infettive
    Torino, Italy
  • Clinical Research Puerto Rico
    San Juan, Puerto Rico
  • Hope Clinical Research Inc
    San Juan, Puerto Rico
  • Bonaventura
    Badalona, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, Spain
  • Hospital Vall d'Hebron
    Barcelona, Spain
  • Hospital Clínico Universitario San Carlos
    Madrid, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, Spain
  • Hospital Costa Del Sol
    Malaga, Spain
  • Karolinska University Hospital
    Stockholm, Sweden
  • Birmingham Heartlands Hospital
    Birmingham, United Kingdom
  • Barts Health NHS Trust
    London, United Kingdom
  • Chelsea and Westminster Hospital
    London, United Kingdom
  • Imperial College
    London, United Kingdom
  • Kings College Hospital NHS Trust
    London, United Kingdom
  • Lewisham and Greenwich NHS Trust
    London, United Kingdom
  • Royal Free Hospital
    London, United Kingdom
  • St. George's Hospital
    London, United Kingdom
  • Manchester Centre for Sexual Health
    Manchester, United Kingdom
09

References and documents

Publications

  • Winston A, Post FA, DeJesus E, Podzamczer D, Di Perri G, Estrada V, Raffi F, Ruane P, Peyrani P, Crofoot G, Mallon PWG, Castelli F, Yan M, Cox S, Das M, Cheng A, Rhee MS. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. Lancet HIV. 2018 Apr;5(4):e162-e171. doi: 10.1016/S2352-3018(18)30010-9. Epub 2018 Feb 20. PubMed 29475804 ↗
  • Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223. PubMed 30932951 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Dec 2017, 29 months.

Results were first posted in Jun 2018, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2015
First posted
Jun 11, 2015
StartActual
Jun 29, 2015
Primary completionActual
Dec 11, 2017
CompletionActual
Mar 13, 2019
Results first posted
Jun 11, 2018
Last update
Oct 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02469246
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
Jun 29, 2015
Primary completion
Dec 11, 2017
Completion
Mar 13, 2019
Results posted
Jun 11, 2018
Last update
Oct 25, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Emtricitabine · Tenofovir alafenamide

Start the discussion